Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis

American Journal of Nephrology

Volumn 27, Issue 6, 2007, Pages 622-629

  Hasuike, Yukiko ^a   Moriguchi, Rintarou ^a   Hata, Reiko ^a   Miyagawa, Kouji ^a   Kuragano, Takahiro ^a   Aizawa, Masayo ^c   Yamamoto, Shigeo ^b   Yanase, Kimihiko ^d   Izumi, Masaaki ^a   Tanimoto, Tsuyoshi ^e   Nakanishi, Takeshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^d Osaka Seamen's Insurance Hospital   (Japan)

^e DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

3 Deoxyglucosone; Aldose reductase; Cancer antigen 125; Chronic renal failure; Mesothelium; Peritoneal dialysis; Polyol pathway

Indexed keywords

3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; CA 125 ANTIGEN; MALONALDEHYDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; EFFLUENT; ERYTHROCYTE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LIPID PEROXIDATION; MALE; MESOTHELIUM; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; DIALYSIS SOLUTIONS; EPITHELIUM; FEMALE; GLUCOSE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PERITONEAL DIALYSIS; PERITONEUM; UP-REGULATION;

EID: 35548961932     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108358     Document Type: Article

References (28)

1. Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J, Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun 1996;225:219-224.
2. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
3. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, Lameire N, Devuyst O: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001;12:2146-2157.
4. Dobbie JW, Lloyd JK, Gall CA: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Periton Dial 1990;6:3-12.
5. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
6. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, van Ypersele de Strihou C, Kurokawa K: Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425-435.
7. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T: High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994;37:328-330.
8. Kato H, Yamamoto M, Fujimaki M: Mechanisms of browning degradation of D-fructose in special comparison with D-glucoseglycine reaction. Agr Biol Chem 1969;33:939-948.
9. Szwergold BS, Kappler F, Brown TR: Identification of fructose 3-phosphate in the lens of diabetic rats. Science 1990;247:451-454.
10. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR: Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 1992;41:778-788.
11. Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N, Takamitsu Y: Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kidney Dis 2002;40:464-471.
12. Koomen GC, Betjes MG, Zemel D, Krediet RT, Hoek FJ: Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 1994;14:132-136.
13. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT: Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995;10:64-69.
14. Blackburn GF, Shah HP, Kenten JH, Leland J, Kamin RA, Link J, Peterman J, Powell MJ, Shah A, Talley DB: Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin Chem 1991;37:1534-1539.
15. Hamada Y, Nishimura C, Koh N, Sakakibara F, Nakamura J, Tanimoto T, Hotta N: Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients. Diabetes Care 1998;21:1014-1018.
16. Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C: Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 2002;91:64-73.
17. Yagi K: Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 1998;108:101-106.
18. Grubb A: Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992;38(suppl 1):S20-S27.
19. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N: Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-753.
20. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M: Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004;53:2404-2411.
21. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003;52:864-871.
22. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
23. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, Goldberg IJ: Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005;115:2434-2443.
24. Ramana KV, Friedrich B, Bhatnagar A, Srivastava SK: Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. FASEB J 2003;17:315-317.
25. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A: Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J 1997;11:181-188.
26. Nakamura N, Obayashi H, Fujii M, Fukui M, Yoshimori K, Ogata M, Hasegawa G, Shigeta H, Kitagawa Y, Yoshikawa T, Kondo M, Ohta M, Nishimura M, Nishinaka T, Nishimura CY: Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 2000;29:17-25.
27. Iwata T, Sato S, Jimenez J, McGowan M, Moroni M, Dey A, Ibaraki N, Reddy VN, Carper D: Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J Biol Chem 1999;274:7993-8001.
28. Crabbe MJ, Peckar CO, Halder AB, Cheng H: Erythrocyte glyceraldehyde-reductase levels in diabetics with retinopathy and cataract. Lancet 1980;ii:1268-1270.